United States

How to build and maintain a requirements traceability matrix for medical devices — linking user needs, design inputs, outputs, risk controls, verification, and validation under FDA 21 CFR 820.30, ISO 13485:2016, IEC 62304, and EU MDR.

Complete guide to FDA 21 CFR Part 11 for medical device companies — electronic records, electronic signatures, audit trails, system validation, CSA guidance, and how Part 11 connects to ISO 13485 and the new QMSR.

Everything you need to prepare for an MDSAP audit — the 2026 updated audit approach (AU P0002.010), QMSR alignment, step-by-step preparation checklist, costs, timelines, and common nonconformities.

A practical regulatory strategy guide for medical device startups — covering FDA pathway selection, budget planning, Q-Sub pre-submissions, eSTAR templates, QMSR compliance, fundraising alignment, and the programs that accelerate market entry in 2026.

A complete guide to medical device complaint handling — regulatory requirements under FDA 21 CFR 820 (QMSR), ISO 13485, and EU MDR, step-by-step process, MDR reportability decisions, CAPA integration, and documentation best practices.

How to classify four common borderline products — hand sanitizer, mouthwash, personal lubricants, and data recorders — across FDA, EU MDR, Brazil ANVISA, and Mexico COFEPRIS. Includes decision trees, regulation citations, and jurisdiction-by-jurisdiction comparison tables.

The complete guide to drug-device combination product regulation — FDA jurisdiction (OCP, RFD, 21 CFR Part 4), EU MDR Article 117, Notified Body Opinions, QMSR changes, CGMP requirements, market pathways, and post-market obligations.

Clause-by-clause gap analysis checklist mapping ISO 13485:2016 to FDA's QMSR — covering terminology changes, complaint handling, labeling controls, UDI integration, record retention, and 50+ specific action items your QMS documents still need.

A complete guide to the regulatory pathway for digital therapeutics — including FDA clearance strategies (510(k), De Novo, PMA), EU MDR classification, Germany's DiGA reimbursement program, approved DTx products, clinical evidence requirements, and what's changing in 2026.

Everything you need to know about validating medical device packaging to ISO 11607 — including sterile barrier systems, material qualification, accelerated aging, distribution simulation, seal strength testing (ASTM F88), bubble leak testing (ASTM F2096), dye penetration, shelf-life claims, FDA and EU MDR requirements, and step-by-step validation workflows.

Data-driven analysis of FDA 510(k) clearance rates, RTA hold rates, NSE decisions, and the most common reasons submissions fail — with actionable strategies to maximize your chances of first-cycle clearance in 2026.

Transparent benchmark of medical device regulatory consulting fees across 16 countries and regions — covering hourly rates by consultant tier, factors that drive cost, and how to budget for registration projects in the US, EU, Japan, Korea, China, India, Brazil, Saudi Arabia, and more.

How the US government and hospital systems procure medical devices — GPO group purchasing organizations (Vizient, Premier, HealthTrust), VA Federal Supply Schedules, DoD procurement, GSA Schedule contracts, SAM.gov registration, and practical strategies for medical device manufacturers seeking to enter the US public-sector supply chain.

Everything you need to know about using real-world evidence (RWE) and real-world data (RWD) for medical device regulatory submissions in 2026 — including the December 2025 FDA final guidance update, acceptable data sources (EHRs, registries, claims databases), relevance and reliability criteria, premarket and postmarket applications, de-identified data policy change, practical steps for incorporating RWE into your regulatory strategy, and comparison with traditional clinical evidence.

Learn how to respond to FDA Form 483 observations and Warning Letters for medical devices. Covers 2025-2026 enforcement statistics, top violations, response strategies, and the March 2026 draft guidance on 483 responses.

Everything you need to know about FDA medical device user fees for FY 2026 (October 2025–September 2026) — covering the complete MDUFA V fee schedule, small business determination program, first PMA waiver, new establishment registration fee waiver, year-over-year comparisons, and strategies to minimize your regulatory costs.

A comprehensive cost breakdown for FDA Premarket Approval (PMA) submissions — covering user fees, clinical trials, consulting, testing, and post-market obligations — with FY 2026-specific figures for Class III medical device manufacturers.

A comprehensive guide to the world's largest medical device companies ranked by revenue — including Medtronic, Johnson & Johnson, Abbott, Siemens Healthineers, and more — with 2026 market data, strategic shifts, and what's driving growth.

A data-driven breakdown of every cost component in a 510(k) submission — FDA user fees, testing, consulting, and hidden expenses — with 2026-specific figures and cost-saving strategies for small businesses.

Everything you need to know about FDA Breakthrough Device Designation — eligibility criteria, application process via Q-Submission, program benefits, statistics, timeline, and how it applies to 510(k), De Novo, and PMA pathways.